Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program
about
"Stormy waters ahead": global emergence of carbapenemasesCurrent concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosaEmergence of Klebsiella pneumoniae carbapenemase-producing bacteriaBeyond Susceptible and Resistant, Part III: Treatment of Infections due to Gram-Negative Organisms Producing CarbapenemasesInsights into Newer Antimicrobial Agents Against Gram-negative BacteriaThe growing burden of antimicrobial resistance.Fatal cross infection by carbapenem-resistant Klebsiella in two liver transplant recipientsInhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial.Ocular penetration of topically applied 1% tigecycline in a rabbit model.Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: a matched case-control study.Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection.Therapy of Infections due to Carbapenem-Resistant Gram-Negative PathogensVaccination with outer membrane complexes elicits rapid protective immunity to multidrug-resistant Acinetobacter baumannii.Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections.Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies.Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniaeComparison of polymyxin B, tigecycline, cefepime, and meropenem MICs for KPC-producing Klebsiella pneumoniae by broth microdilution, Vitek 2, and Etest.Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urineCharacterization of BKC-1 class A carbapenemase from Klebsiella pneumoniae clinical isolates in Brazil.Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports.Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipientCefepime: a reappraisal in an era of increasing antimicrobial resistance.Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy?Polymyxins revisited.In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.Establishing the role of tigecycline in an era of antimicrobial resistance.Multiresistant Enterobacteriaceae: new threat of an old problem.Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.New information about the polymyxin/colistin class of antibiotics.Status report on carbapenemases: challenges and prospects.When and how to cover for resistant gram-negative bacilli in severe sepsis and septic shock.Pharmacokinetic and pharmacodynamic evaluation of tigecycline.The epidemiology of the first described carbapenem-resistant Klebsiella pneumoniae outbreak in a tertiary care hospital in Saudi Arabia: how far do we go?Klebsiella pneumoniae carbapenemases in Enterobacteriaceae: history, evolution, and microbiology concerns.Coexistence of Extended Spectrum Beta-Lactamases, AmpC Beta-Lactamases and Metallo-Beta-Lactamases in Acinetobacter baumannii from burns patients: a report from a tertiary care centre of India.Carbapenemase-producing Gram-negative bacteria: current epidemics, antimicrobial susceptibility and treatment options.Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012).
P2860
Q21131125-A4FCA1E7-025B-4D01-AB07-EF8ED2AAAE06Q24612271-6CFF4940-9FC2-428A-9329-C4EF35D97CCFQ24618178-349D7B00-F04F-4657-83A0-967BDFF82E2FQ26747580-E2CB48DC-8DFE-4B39-8EC3-38BB20B29B72Q26751255-B7D3D8F1-8ED1-4500-B0C5-F2F1286F9F35Q30371239-E73A12B4-7E49-4E06-954A-12570EC9B2A2Q30433281-CF86DC9F-F7E0-456A-B2C7-194DB61903F0Q33613797-E728299D-7A84-41BB-8D56-47B466479CCFQ33642184-F6CD2F45-81C6-49BA-BE36-D5B7E85464C3Q33706051-86CF5FB1-16CA-4901-934B-E7ADC92D01A9Q33909443-216F24B3-1A29-43E0-8D30-694E21918665Q34109281-150E43D8-EBDF-45F8-9C17-43EC30F8099FQ34303970-2DE682F4-D6FF-4080-A342-A7716B291CDAQ34484474-7CCE3DD4-9EE4-485E-9C0B-EBF1714C536CQ34678004-E452CDA8-DC5D-4166-81AE-74584ADFFBEDQ34803735-8032A99D-94A0-4FDE-94EB-4B7367C152CAQ35005216-B9E57272-84CB-4312-B799-DCD4FC7341A9Q35066622-7AA57EB1-1591-4219-ABE6-8062F5F7961AQ35598359-DF3C198D-ED06-481C-9411-A6C614DF67AAQ35960662-E6C6F61F-DDBF-4C7A-8417-027A4537568CQ36556499-EECDCCD6-C02D-46EA-9366-8401006CD921Q36761826-B4E1A6C9-30B3-40A3-95C5-2D5F79572A39Q37032821-B8A577F9-76FF-4017-AC71-D1BDCF3EF2AFQ37079350-829D6941-F2AA-4916-8772-47391BF4387CQ37146405-85E4176B-CFED-4C94-B1A1-C2A004268D55Q37215935-79D689C4-355F-4E51-9859-356720FC18CFQ37247732-AAB8B19E-6BAE-48C6-ACC2-988F07742202Q37291328-ABC66EBE-F773-4922-A9C6-FD63D47769EDQ37291349-54FB09C5-126A-48D1-9D17-43C32E3757E7Q37333088-2C40DBBE-86BD-45E7-A91B-631E0E35DC90Q37392725-3A17D8EB-1A18-42B7-A11D-A739D52270D4Q37636150-D97276F6-2D22-4C5A-A89E-501DF3CA63D2Q37879199-FA03B794-1554-4F3C-BFC1-97ECF890230BQ37907967-A63802AB-C85E-4296-8829-6A6C3C562A82Q37940546-9B464570-8823-45BD-93CB-0C6CA5218514Q37975111-5DD94BF3-35EC-4141-BF95-F57378266D2EQ38001333-9E9B33FA-CF75-4731-8F89-B22CF77008C2Q38209657-86F188DE-7ECC-42B1-9D67-37EEB4D65C63Q38392082-3A4B3AA0-D1E3-4439-B7DF-AF4DEC1D22E4Q39683665-05737F8C-E705-4CFD-9F24-F6D82CD0EFB1
P2860
Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Antimicrobial activities of ti ...... microbial Surveillance Program
@ast
Antimicrobial activities of ti ...... microbial Surveillance Program
@en
type
label
Antimicrobial activities of ti ...... microbial Surveillance Program
@ast
Antimicrobial activities of ti ...... microbial Surveillance Program
@en
prefLabel
Antimicrobial activities of ti ...... microbial Surveillance Program
@ast
Antimicrobial activities of ti ...... microbial Surveillance Program
@en
P2093
P2860
P356
P1476
Antimicrobial activities of ti ...... microbial Surveillance Program
@en
P2093
Hélio S Sader
Lalitagauri M Deshpande
Ronald N Jones
Thomas R Fritsche
P2860
P304
P356
10.1128/AAC.01114-07
P407
P577
2007-12-10T00:00:00Z